Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CECLOR CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CECLOR CD.
ARBLI vs CECLOR CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
10 mg orally once daily.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: ~80% unchanged; biliary/fecal: ~20%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic